# US 2026/0076947 A1 · Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076947 A1
- Document ID: US20260076947A1
- Status: Published application
- Kind: A1
- Application number: 19/330,600
- Filed: 2025-09-16
- Published: 2026-03-19
- Earliest claimed: 2022-01-19
- Assignees: Northwestern University; The University of Chicago
- Applicants: Northwestern University; The University of Chicago
- Inventors: Karl A. Scheidt; Stephen J. Kron; Yue Liu
- Web page: https://patentgrep.com/patent/US20260076947A1

## CPC

- A61K 31/4192: 1,2,3-Triazoles
- A61P 35/00: Antineoplastic agents
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for reducing or preventing resistance or recurrence of a tumor in a subject administered a genotoxic therapy, the method comprising co-administering an inhibitor of telomerase reverse transcriptase (TERT) with the genotoxic therapy to the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein administering the inhibitor of TERT to the subject inhibits induction of an immunosuppressive factor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the immunosuppressive factor is an immune checkpoint protein, a cytokine, a chemokine, an enzyme, or any combination thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the immune checkpoint protein is PD-L1.

### Claim 27 (depends on 23)

The method of claim 23, wherein administering the genotoxic therapy induces a transient immune response.

### Claim 28 (depends on 23)

The method of claim 23, wherein the subject is administered an amount of the genotoxic therapy which is therapeutic but not uniformly curative in the absence of administration of the inhibitor of TERT.

### Claim 29 (depends on 23)

The method of claim 23, wherein the subject is administered a non-therapeutic amount of the inhibitor of TERT to treat the subject.

### Claim 30 (depends on 23)

The method of claim 23, wherein the genotoxic therapy is administered after administration of the inhibitor of TERT.

### Claim 31 (depends on 23)

The method of claim 23, wherein the genotoxic therapy is a radiotherapy or chemotherapy.

### Claim 32 (depends on 23)

The method of claim 23, wherein the subject has a disease or disorder associated with TERT activity.

### Claim 33 (depends on 23)

The method of claim 23, wherein the tumor is (1) a tumor of the adrenal gland, bladder, blood, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, prostate, skin, testis, thymus, or uterus or (2) an adenocarcinoma, a leukemia, a lymphoma, a melanoma, a myeloma, a sarcoma, an embryonal malignancy, or a teratocarcinoma.

### Claim at position 13

34-35. (canceled)

### Claim 36 (depends on 23)

The method of claim 23, wherein the inhibitor of TERT is a covalent inhibitor of TERT.

### Claim 37 (depends on 36)

The method of claim 36, wherein the inhibitor of TERT is a 3-methylideneoxan-4-one compound or a derivative thereof as disclosed herein.

### Claim 38 (depends on 37)

The method of claim 37, wherein the inhibitor of TERT is:

### Claim 39 (depends on 23)

The method of claim 23, wherein the inhibitor of TERT is a reversible inhibitor of TERT.

### Claim 40 (depends on 23)

The method of claim 23, wherein the subject is co-administered an immunotherapy or a molecularly targeted therapy.

### Claim 41 (depends on 40)

The method of claim 40, wherein the subject is co-administered the immunotherapy after administration of the inhibitor of TERT.

### Claim 42 (depends on 23)

The method of claim 23, wherein the subject is co-administered a molecularly targeted therapy.

### Claim 43 (depends on 42)

The method of claim 42, wherein the subject is co-administered the molecularly targeted therapy after administration of the inhibitor of TERT.

### Claim at position 22

44-82. (canceled)
